These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23829278)

  • 21. Influence of MTHFR C677T Polymorphism on High-Dose Methotrexate-Related Toxicity in Patients With Primary Central Nervous System Diffuse Large B-Cell Lymphoma.
    Chang X; Guo Y; Su L; Zhang Y; Hui W; Zhao H; Hu R; Sun W
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):91-96. PubMed ID: 33069634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
    Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methotrexate elimination and toxicity: MTHFR 677C>T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexate.
    Choi YJ; Park H; Lee JS; Lee JY; Kim S; Kim TW; Park JS; Kim JE; Yoon DH; Suh C
    Hematol Oncol; 2017 Dec; 35(4):504-509. PubMed ID: 27781293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
    Seidemann K; Book M; Zimmermann M; Meyer U; Welte K; Stanulla M; Reiter A
    Ann Hematol; 2006 May; 85(5):291-300. PubMed ID: 16463153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Relationship between the methylenetetrahydrofolate reductase gene polymorphism and adverse reactions of high-dose methotrexate in children with acute lymphocytic leukemia].
    Zheng MM; Yue LJ; Chen XW; Wen FQ; Li CG; Yang CL; Xie C; Ding H
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Mar; 15(3):201-6. PubMed ID: 23498762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylene tetrahydrofolate reductase genotypes frequencies: association with toxicity and response to methotrexate in rheumatoid arthritis patients.
    Saleh MM; Irshaid YM; Mustafa KN
    Int J Clin Pharmacol Ther; 2015 Feb; 53(2):154-62. PubMed ID: 25492850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MTHFR gene polymorphisms and methotrexate toxicity in adult patients with hematological malignancies: a meta-analysis.
    Zhao M; Liang L; Ji L; Chen D; Zhang Y; Zhu Y; Ongaro A
    Pharmacogenomics; 2016 Jun; 17(9):1005-17. PubMed ID: 27270164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic markers in methotrexate treatments.
    Giletti A; Esperon P
    Pharmacogenomics J; 2018 Dec; 18(6):689-703. PubMed ID: 30237581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methylenetetrahydrofolate reductase gene polymorphisms (677C > T and 1298A > C) in Egyptian patients with non-Hodgkin lymphoma.
    Nasr AS; Sami RM; Ibrahim NY
    J Cancer Res Ther; 2012; 8(3):355-60. PubMed ID: 23174714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population.
    Cáliz R; del Amo J; Balsa A; Blanco F; Silva L; Sanmarti R; Martínez FG; Collado MD; Ramirez Mdel C; Tejedor D; Artieda M; Pascual-Salcedo D; Oreiro N; Andreu JL; Graell E; Simon L; Martínez A; Mulero J
    Scand J Rheumatol; 2012 Feb; 41(1):10-4. PubMed ID: 22044028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
    Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
    Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients.
    Toffoli G; Russo A; Innocenti F; Corona G; Tumolo S; Sartor F; Mini E; Boiocchi M
    Int J Cancer; 2003 Jan; 103(3):294-9. PubMed ID: 12471611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico.
    Ruiz-Argüelles GJ; Coconi-Linares LN; Garcés-Eisele J; Reyes-Núñez V
    Hematology; 2007 Oct; 12(5):387-91. PubMed ID: 17891601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.
    Salazar J; Altés A; del Río E; Estella J; Rives S; Tasso M; Navajas A; Molina J; Villa M; Vivanco JL; Torrent M; Baiget M; Badell I
    Pharmacogenomics J; 2012 Oct; 12(5):379-85. PubMed ID: 21747412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship Between Polymorphisms in Methotrexate Pathway Genes and Outcome of Methotrexate Treatment in a Cohort of 119 Patients with Juvenile Idiopathic Arthritis.
    Zajc Avramovič M; Dolžan V; Toplak N; Accetto M; Lusa L; Avčin T
    J Rheumatol; 2017 Aug; 44(8):1216-1223. PubMed ID: 28572465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MTHFR C677T polymorphism: association with lymphoid neoplasm and effect on methotrexate therapy.
    Ayad MW; El Naggar AA; El Naggar M
    Eur J Haematol; 2014 Jul; 93(1):63-9. PubMed ID: 24592886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome.
    Lima A; Bernardes M; Azevedo R; Seabra V; Medeiros R
    Pharmacogenomics; 2016 Oct; 17(15):1649-1674. PubMed ID: 27676277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia.
    Kałużna E; Strauss E; Zając-Spychała O; Gowin E; Świątek-Kościelna B; Nowak J; Fichna M; Mańkowski P; Januszkiewicz-Lewandowska D
    Eur J Pharmacol; 2015 Dec; 769():93-9. PubMed ID: 26528799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
    Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
    Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic Determinants of Methotrexate Toxicity in Tunisian Patients with Rheumatoid Arthritis: A Study of Polymorphisms Involved in the MTX Metabolic Pathway.
    Chaabane S; Marzouk S; Akrout R; Ben Hamad M; Achour Y; Rebai A; Keskes L; Fourati H; Bahloul Z; Maalej A
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):385-93. PubMed ID: 26077125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.